Cannabis News

Aegis Sciences Corporation Launches Key Opinion Leadership Series With First Panel on Designer Drugs

The first panel will feature experts from across the country to discuss the impact of this outbreak on healthcare

NASHVILLE, Tenn.–(BUSINESS WIRE)–Aegis Sciences Corporation launches a series of key opinion leaders titled “In Practice: Clinical Insights” on July 26. The panel will feature healthcare experts from across the country. This series will consist of timely panel discussions on topics affecting the healthcare industry and the myriad ways testing can shed light on these issues, including the evolution of the designer drug market, plans for addiction recovery, the effective use of medication monitoring, etc. .

The first installation of the series, “Designer drugs: coping with the impact. Formulating the Solution,” will take place on Tuesday, July 26 at 10:00 a.m. PT, 11:00 a.m. MT, 12:00 p.m. CT, and 1:00 p.m. ET. The inaugural panel will focus on the current state of synthetic drugs in the United States, the evolution of the drug market, and the impact of designer drugs for communities and the healthcare field.

Joshua Schrecker, Pharm.D., director of clinical affairs at Aegis, will serve as moderator. The panelists will be:

  • Kevin Fischer, MD, Chief Medical Officer of Columbia River Mental Health Services. Fischer is board certified in addiction medicine and internal medicine and provides patient care through the NorthStar Opioid Treatment Program.
  • Amy West, MSN, FNP-C, Family Nurse Practitioner for Penobscot Community Healthcare. West works as a family nurse practitioner, specializing in adolescent health, women’s health, and street medicine for homeless people.
  • Alex Krotulski, Ph.D., associate director at the Center for Forensic Science Research & Education. Krotulski is the program manager for NPS Discovery, CFSRE’s drug early warning system and flagship program for the identification and characterization of new and emerging synthetic drugs.
  • Bryce Pardo, Ph.D., Associate Director, Center for Drug Policy Research and Policy Researcher at the RAND Corporation. Pardo focuses on drug policy with particular interest in the areas of cannabis regulation, opioid control, and markets for new psychoactive substances.

Panelists will discuss the history of synthetic drugs and their variation in prevalence and composition over time, as well as the impact of synthetic drug exposure on individuals during clinical care. They will cover how laboratories and healthcare organizations identify synthetic drugs in biological samples and the complexity of testing needed to keep up with an ever-changing drug supply, as well as recent national trends related to drug use. synthetic drugs and national efforts to reduce the increase in drug overdose deaths.

To register for July 26 »Designer drugs: coping with the impact. Formulate the solution. session, please register here.

About Aegis Sciences Corporation

Founded in 1990, Aegis Sciences Corporation is a Nashville, TN-based laboratory science company that provides science-based testing and consulting services to customers including healthcare providers, pharmaceutical companies , professional and amateur sports organizations, major colleges and universities. programs, Fortune 500 companies and government agencies across the United States. For more information, please visit


Amanda Reinbold

MP&F Strategic Communications

This Publish was originally published on This site

#Aegis #Sciences #Corporation #Launches #Key #Opinion #Leadership #Series #Panel #Designer #Drugs

Related Posts

Leave a Reply